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Objective: The aim of this study was to examine a potential
association between omalizumab and cardiovascular (CV)/
cerebrovascular (CBV) events in EXCELS.
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allergic asthma and who were being treated with omalizumab
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on the subset of arterial thromboembolic events (ATEs),
comprising CV death, myocardial infarction, ischemic stroke,
transient ischemic attack, and unstable angina. A prespecified
analysis of the end point of ATE was conducted to control for
available potential confounders. A blinded independent expert
panel adjudicated all events.
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Omalizumab-treated patients had a higher rate of CV/CBV
serious adverse events (13.4 per 1,000 person years [PYs]) than
did non–omalizumab-treated patients (8.1 per 1,000 PYs). The
ATE rates per 1,000 PYs were 6.66 (101 patients/15,160 PYs) in
the omalizumab cohort and 4.64 (46 patients/9,904 PYs) in the
non-omalizumab cohort. After control for available
confounding factors, the hazard ratio was 1.32 (95% CI,
0.91-1.91).
Conclusion: This observational study demonstrated a higher
incidence rate of CV/CBV events in the omalizumab versus the
non-omalizumab cohort. Differences in asthma severity between
cohorts likely contributed to this imbalance, but some increase
in risk cannot be excluded. (J Allergy Clin Immunol
2016;nnn:nnn-nnn.)
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Omalizumab (Xolair; Genentech, Inc, South San Francisco,
Calif) is a recombinant humanized monoclonal antibody
directed against IgE. In randomized, placebo-controlled
trials and in open-label studies in patients onmaintenance therapy
with inhaled corticosteroids (ICSs) and/or long-actingb-agonists,
the addition of omalizumab has been shown to reduce
asthma exacerbations,1-9 decrease the use of ICSs and rescue
medications,1,3,5,8,10 and improve symptom control and quality
of life.1,5,8,10
In EXCELS (Epidemiologic Study of Xolair [Omalizumab]:
Evaluating Clinical Effectiveness and Long-term Safety in
Patients With Moderate to Severe Asthma), a postmarketing
observational cohort study, the primary objectivewas to assess the
long-term (<_5 years) clinical safety profile of omalizumab, with a
focus on malignancy. This observational study was designed to
compare adverse events in patients with asthmawhom health care
providers had treated with omalizumab to those in patients with
asthma who had not been treated with omalizumab. A numeric
imbalance in malignancy rates in patients with allergic asthma in
pivotal trials was the motivation for EXCELS.3,5 Accordingly, the
primary outcomemeasures were primarymalignancies, all malig-
nancies excluding nonmelanoma skin cancer, and overall serious
adverse events (SAEs). Details regarding the study design and
methodology, including patients’ baseline characteristics, have
been published elsewhere.11 In EXCELS, the incidence rates of
primary malignancies (per 1000 person years [PYs]) were similar1
J ALLERGY CLIN IMMUNOL
nnn 2016
2 IRIBARREN ET ALAbbreviations usedATE: Arterial thromboembolic eventCBV: CerebrovascularCV: CardiovascularEXCELS: Epidemiologic Study of Xolair (Omalizumab): Evaluating
Clinical Effectiveness and Long-term Safety in Patients
With Moderate to Severe AsthmaFDA: US Food and Drug AdministrationICS: Inhaled corticosteroidMI: Myocardial infarctionOCS: Oral corticosteroidPY: Person yearSAE: Serious adverse eventamong patients treated with omalizumab and non–omalizumab-
treated patients (12.3 vs 13.0); however, study limitations
precluded definitively ruling out a malignancy risk with
omalizumab.12 In an interim effectiveness analysis, patients
who started on treatment with omalizumab at enrollment showed
clinically relevant improvements in asthma control that were
maintained during 2 years of follow-up.13
This analysis focused on cardiovascular (CV) and cere-
brovascular (CBV) SAEs that occurred during EXCELS.
EXCELS was not originally designed specifically to assess
CV/CBV events. A numeric imbalance in various CV/CBV
events was first observed in an interim analysis presented to
the US Food and Drug Administration (FDA), prompting a
disclosure of such findings by the FDA in 2009.14 The
interim analysis also resulted in the development of a
prespecified statistical analysis plan supporting methodology
for the ascertainment of CV-related events, including external
adjudication, as detailed subsequently. An analysis of data
pooled from multiple randomized, double-blind, placebo-
controlled clinical trials of omalizumab was also planned
after the results from the EXCELS interim analysis were
evaluated.15METHODS
Overview of EXCELS
EXCELS (ClinicalTrials.gov identifier: NCT00252135) was conducted as
part of a postmarketing commitment to the FDA to assess the long-term safety
and effectiveness of omalizumab in the clinical practice setting. Patients
(>_12 years of age; N 5 7857) with moderate to severe asthma, willing to
participate in a 5-year study, and with a history of either a positive response
to allergy skin testing or in vitro serum–specific IgE reactivity to an
aeroallergen were recruited from 445 US-based practice centers according
to the use of omalizumab at or within 30 days of enrollment (2:1 ratio;
omalizumab, n5 5007; non-omalizumab, n5 2829). Patients were excluded
from EXCELS if they had: (1) a contraindication to omalizumab; (2) an
asthma exacerbation that required initiation or increased doses of systemic
corticosteroids, doubling of inhaled corticosteroid dosing, or an emergency
department visit or hospitalization in the 2 weeks before screening; (3) acute
flare of significant systemic disease or hospitalization for that disease in the
2 months prior to screening; and/or (4) use of an experimental drug within
30 days of screening, cystic fibrosis diagnosis, or participation in a blinded
omalizumab study at screening or any time during the study. Patients in the
non-omalizumab group could not have received any prior treatment with
omalizumab. A small number of patients (n 5 21) who had previously been
treated with omalizumab but were not taking the drug at study enrollment
were not included in the analyses. Assessments included the collection of
detailed information regarding demographic and clinical characteristics,physician-assessed asthma severity, spirometry, and patient-reported outcome
measures. Study assessments were conducted every 6 months for the 5-year
study duration.
This study was conducted in accordance with FDA regulations, the
International Conference on Harmonisation E6 Guideline for Good Clinical
Practice, and any other applicable country laws. Institutional review board
approval was obtained at each study site, and informed consent was obtained
from all research subjects.Identification and adjudication of CV and CBV SAEs
In EXCELS, the definition of an SAE was any untoward medical
occurrence that, after enrollment, resulted in a patient’s death, was
life-threatening, required prolonged inpatient hospitalization, was disabling,
was a congenital anomaly/birth defect, or was medically significant or
required medical or surgical intervention to prevent one of these outcomes,
and was based on the definition of an SAE as outlined by the FDA.16
During EXCELS, verbatim terms for all study-emergent SAEs were
coded and analyzed using the Medical Dictionary for Regulatory Activities
(MedDRA) System Organ Classes, High-Level Terms, and Preferred
Terms. An independent panel of experts performed a blinded review of
patient narratives and supporting documents for all SAEs that resulted in
death and all potential CV/CBV SAEs identified using Standardized
MedDRA Queries (Medical Dictionary for Regulatory Activities; http://
www.meddra.org/standardised-meddra-queries) (Fig 1). This approach
allowed for the identification of cases that were highly likely to have
represented the condition of interest as well as the identification of all
possible cases. The panel also classified the CV/CBV SAEs into
standardized categories: myocardial infarction (MI), unstable angina,
congestive heart failure, ischemic stroke, transient ischemic attack,
hemorrhagic stroke, pulmonary embolism, venous thrombosis, pulmonary
hypertension, arterial ischemic vascular disease, atrial fibrillation/flutter,
and ventricular tachycardia/fibrillation.
An additional composite end point, arterial thromboembolic event (ATE),
was defined using an approach adapted from the 2002 Antiplatelet Trialists’
Collaboration.17 The ATE category comprised CV/CBV events sharing a
common pathophysiologic mechanism of arterial injury and/or inflammation
and included CV death, MI, ischemic stroke, transient ischemic attack, and
unstable angina.Descriptive analyses
Datawere analyzed in terms ofPYs of observation, defined as the time from
study day 0 to the date of death, date of event of interest, study completion, or
the last completed clinic visit in those who discontinued from the study,
whichever came first. Overall incidence rates per 1000 PYs of observation
of adjudicated CV/CBV-related deaths and SAEs were calculated in
each cohort and are reported with 95% CIs. Crude rate differences were
calculated with 95% CIs. The same analyses were performed for each of the
adjudicated event categories and for all event categories combined (CV or
CBV SAEs).
The prespecified analysis of ATEs was applied to the cumulative
adjudicated data for the evaluation of events with a common pathophysiology.
As described for CV/CBV SAEs, overall incidence rates per 1000 PYs were
calculated with 95% CIs for both cohorts. Crude rate differences and rate
ratios were calculated with 95% CIs. Similarly, the rates of patients
experiencing >_1 ATE event, expressed per 1000 PYs of observation time,
were calculated by treatment cohort and reported with 95% CIs. A sensitivity
analysis was conducted in which event rates per 1000 PYs were computed by
treatment cohort for the set of ATEs that excluded deaths not associated with
any of the following SAEs: MI, ischemic stroke, ventricular tachycardia, or
ventricular fibrillation.
To adjust for potential confounders, we used a Cox proportional hazards
regression model. The time to a patient’s first ATE was defined as the number
of months from study day 0 to the date of onset of symptoms of the first SAE
experienced by the patient that met the ATE definition. Data from
patients not experiencing anATEwere censored at the earliest of the following
FIG 1. Identification and adjudication of CV and CBV events. MedDRA, Medical Dictionary for Regulatory
Activities; SMQ, Standardized Medical Dictionary for Regulatory Activities Query.
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ation from the study, initiation of omalizumab treatment (non-omalizumab
cohort only), >6 months after the omalizumab stop date (omalizumab cohort
only), or study completion. ACox proportional hazards model was fit for time
to first study-emergent ATE to estimate the unadjusted hazard ratio between
treatment cohorts and corresponding 95% CIs. Models were subsequently fit
for time to first study-emergent ATE to estimate the hazard ratio between
cohorts, with adjustments separately for each potential baseline CV/CBV
risk factor. A final multivariate Cox proportional hazards model was
developed to adjust fully for all available baseline CV/CBV risk factors,
according to the prespecified analysis plan, with covariates for age
(<65 vs >_65 years), sex, and asthma severity (severe vs moderate). Stepwise
variable selection was then used to select a final model from potential
baseline risk factors based on P <_.20 criteria for entry and P >.20 for removal.
Model covariates can be found in Table E1 in this article’s Online Repository
at www.jacionline.org.
In addition, a post hoc exploratory analysis was conducted to compare
ATE risk between the omalizumab and non-omalizumab cohorts, with
adjustment for the estimated probability of receiving omalizumab. In
each patient, a propensity score18 was calculated using logistic regression
to model the probability of receiving omalizumab as a function of
potentially confounding baseline variables, including, but not limited to,
age, race, ethnicity, sex, investigator-assessed asthma severity, IgE level,
selected asthma and allergy history, and non–asthma-related medical
history, as well as selected socioeconomic characteristics and variables
specific to CV risk factors. Subsequent to trimming all nonoverlapping
propensity score values between treatment cohorts, an additional 1% of
observations were removed from the upper tail of the propensity score
distribution in the omalizumab-treated group, in addition to removal of
1% of observations from the lower tail of the propensity score distribution
in the non–omalizumab-treated group. Patients were then stratified into
deciles according to each patient’s propensity score. A standardized
incidence rate per 1000 PYs was calculated for each treatment cohort,
as well as a standardized rate difference and a rate ratio (using the
omalizumab cohort as the standard).
Kaplan-Meier estimates were used for summarizing the distribution of time
to first adjudicated study-emergent ATE SAE. All analyses were performed
using SAS software version 9.2 (SAS Institute, Cary, NC).RESULTS
PYs of follow-up
In the omalizumab cohort, the total cumulative PYs were
18,426 (mean6 SD duration of follow-up, 3.76 1.8 years); in the
non-omalizumab cohort, the total cumulative PYs were 9,963
(duration of follow-up, 3.5 6 1.9 years).
Patient disposition
Baseline demographic and clinical characteristics have been
previously reported.12 On average, the omalizumab cohort was
slightly younger than the non-omalizumab cohort (44 vs 46 years,
respectively). In both cohorts,;65% were female and 80% were
white. Clinical characteristics and CV risk factors are shown in
Table I. Fifty-six percent of all patients remained in the study
for 5 years and completed a clinic visit at month 60. The most
frequently reported reasons for early discontinuation in the
omalizumab and non-omalizumab groups, respectively, were
patient decision (18% and 15%), loss to follow-up (16% and
15%), and physician decision (8% and 6%). In terms of
person-time lost to follow-up, the proportions lost to follow-up
were 26.4% in the omalizumab cohort and 29.6% in the
non-omalizumab cohort.
The percentage of patients with severe asthma in the omalizu-
mab cohort was more than twice that in the non-omalizumab
cohort (49.6% vs 22.6%, respectively). Among patients with
moderate asthma in the omalizumab cohort, 78.1% had used an
asthma controller and 15.6% had used a quick-relief medication,
in the 2 weeks before enrollment. In the non-omalizumab cohort,
during the same time period, 69.8% of patients with moderate
asthma had used an asthma controller and 11.9% had used a
quick-relief medication. In both groups, the majority of patients
with severe asthmawere taking an ICS or long-acting ß-agonist to
control their symptoms (see Table E2 in this article’s Online
Repository).
TABLE I. Baseline clinical characteristics of the study cohorts
Characteristic Non-omalizumab cohort (n 5 2,829) Omalizumab cohort (n 5 5,007)
Age, means 6 SDs (y) 46 6 17 (n 5 2,827) 44 6 17 (n 5 5,006)
Female, no. (%) 1,880* (66.5) 3,199 (63.9)
White, no. (%) 2,322* (82.2) 3,949* (78.9)
BMI, means 6 SDs (kg/m2) 31.0 6 12.9 (n 5 2,824) 31.1 6 11.9 (n 5 4,996)
Smoking habit, no. (%) n 5 2,827 n 5 5,005
Current 159 (5.6) 245 (4.9)
Former 826 (29.2) 1477 (29.5)
IgE, median (range) (IU/mL) 108 (0-23,237) (n 5 2,728) 202 (2.0-33,200) (n 5 4,998)
Physician-assessed asthma severity, no. (%) n 5 2,822 n 5 5,001
Moderate 2,185 (77.4) 2,519 (50.4)
Severe 637 (22.6) 2,482 (49.6)
Comorbidities, no. (%)
Hypertension 658 (23.3) 1,078 (21.5)
Hypercholesterolemia 306 (10.8) 516 (10.3)
Coronary artery disease 73 (2.6) 122 (2.4)
Congestive heart failure 26 (0.9) 64 (1.3)
Type 2 diabetes 189 (6.7) 430 (8.6)
Depression 417 (14.7) 864 (17.3)
Chronic obstructive pulmonary disease 161 (5.7) 407 (8.1)
OCS use, no. (%) n 5 2,822 n 5 4,997
Any 724 (25.7) 1,407 (28.1)
Chronic 156 (5.5) 373 (7.5)
Periodic 568 (20.1) 1,034 (20.7)
BMI, Body mass index.
*Non-omalizumab cohort, female, n 5 2,827, white, n 5 2,826; omalizumab cohort, white, n = 5,006.
Reported oral corticosteroid use in the past 12 months at the baseline visit.
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versus non–omalizumab-treated patients reported chronic oral
corticosteroid (OCS) use (7.5% vs 5.5%, respectively), which
might be attributable to the larger percentage of omalizumab-
versus non–omalizumab-treated patients with moderate asthma
taking OCSs (27.6% vs 24.4%, respectively; see Table E2 in this
article’s Online Repository). During the 5-year follow-up, more
patients with severe asthma, regardless of treatment cohort,
were taking an OCS than were those with moderate asthma (see
Fig E1 in this article’s Online Repository). The overall pattern
of OCS use was similar; the lowest use rate was measured at
month 6 (range, 17% to 33%), and the highest use rate was
measured at month 18 (range, 20% to 52%). Overall, the use of
OCSs at baseline was higher among patients with severe versus
moderate asthma (29% vs 26%, respectively).Adjudicated study-emergent CV/CBV SAEs
A higher incidence rate of CV/CBV SAEs was observed in the
omalizumab-treated group (13.4 per 1000 PYs; 95% CI,
11.6-15.4) compared with the non–omalizumab-treated group
(8.1 per 1000 PYs; 95%CI, 6.5-10.1) (Table II). Higher rates were
observed, respectively, for transient ischemic attack (0.7 vs 0.1
per 1000 PYs), MI (2.1 vs 0.8 per 1000 PYs), pulmonary
hypertension (0.5 vs 0.0 per 1000 PYs), pulmonary embolism/
venous thrombosis (3.2 vs 1.5 per 1000 PYs), and unstable angina
(2.2 vs 1.4 per 1000 PYs), while the rates observed for ischemic
stroke and CV death were similar among both study cohorts.Adjudicated study-emergent ATEs
The omalizumab cohort had higher rates (per 1000 PYs) of
ATE SAEs, patients with ATE SAEs, and ATE SAEs (excludingnon-ATE deaths) than did the non-omalizumab cohort (see Table
E3 in this article’s Online Repository).
The unadjusted (crude) rates of ATEs per 1,000 PYs were 6.66
(101 patients with an ATE event per 15,160 PYs) in the
omalizumab cohort and 4.64 (46 patients with an ATE event per
9,904 PYs) in the non-omalizumab cohort. The difference
between the omalizumab and non-omalizumab cohorts in ATE
rates per 1000 PYs was 2.02 (95% CI, 0.15-3.89), and the
unadjusted rate ratio was 1.43 (95% CI, 1.00-2.08) (see Table E4
in this article’s Online Repository). The adjusted Cox
proportional hazards analysis indicated a hazard ratio of ATE
events among those treated with omalizumab, compared with
those who did not take omalizumab, of 1.32 (95% CI,
0.91-1.91; Table III). After adjustment for the estimated
probability of receiving omalizumab (propensity score), the
difference between cohorts in ATE rates was 1.55 per 1000 PYs
(95% CI, 20.87 to 3.97), and the rate ratio was 1.32 per 1000
PYs (95% CI, 0.83 to 2.12). The Kaplan-Meier estimates of
time to first adjudicated study-emergent ATE are shown in Fig 2.DISCUSSION
Omalizumab has proven efficacy as adjunctive therapy in the
management of moderate to severe allergic asthma.1-9 EXCELS
was conducted to collect longer-term safety data on omalizumab
after approval. The results from the primary analysis of overall
SAEs and malignancy have been previously published.12 The
current analysis of the EXCELS data revealed a higher crude
incidence rate of CV/CBV SAEs in omalizumab-treated patients
compared with non–omalizumab-treated patients. However, in
the results from analyses of data pooled from 25 studies,15 an
association between omalizumab and CV/CBV SAEs or ATEs
was not demonstrated.
TABLE II. Crude incidence rate (per 1000 PYs) of study-emergent CV/CBV SAEs*
Parameter
Non-omalizumab cohort (n 5 2829) Omalizumab cohort (n 5 5007)
No. of
events
Crude incidence
rate per 1000 PYs 95% CI
No. of
events
Crude incidence
rate per 1000 PYs 95% CI
Any CV/CBV event 80 8.1 6.5-10.1 201 13.4 11.6-15.4
MI 8 0.8 0.3-1.6 32 2.1 1.4-3.0
Unstable angina 14 1.4 0.8-2.4 33 2.2 1.5-3.0
Transient ischemic attack 1 0.1 0.0-0.6 11 0.7 0.4-1.3
Pulmonary embolism/venous thrombosis 15 1.5 0.8-2.5 49 3.2 2.4-4.3
Pulmonary hypertension 0 0 0.0-0.4 8 0.5 0.2-1.0
Ischemic stroke 7 0.7 0.3-1.4 8 0.5 0.2-1.0
CV-related death 20 2.0 1.2-3.1 36 2.4 1.6-3.3
*Estimates are reflective of the number of patients and not the number of occurrences of each event, and on the PYs at risk for each individual event, not the overall PYs at risk for
any event during the study.
TABLE III. Hazard ratio (HR) for adjudicated study-emergent
ATE SAEs
Parameter
Non-omalizumab
cohort* (n 5 2,829)
Omalizumab
cohorty (n 5 5,007)
No. of ATE SAEs 46 101
PYs at risk for ATE SAEs 9,904 15,160
Unadjusted HR (95% CI) 1.47 (1.04-2.08)
Adjusted HR§ (95% CI) 1.32 (0.91-1.91)
*All non–omalizumab- or omalizumab-treated patients before any change in baseline
treatment status.
After initiation of omalizumab treatment (non-omalizumab cohort) or >6 months
after last omalizumab dose (omalizumab cohort).
Defined as the time from day 0 to the earliest of the following events: study
completion, death, first ATE SAE, start of omalizumab treatment (non-omalizumab
cohort), >6 months after discontinuation of omalizumab (omalizumab cohort), or the
last completed study visit date (discontinued patients). For patients who changed
omalizumab treatment status, PYs at risk were calculated from omalizumab start date
(non-omalizumab cohort) or >6 months after the end date (omalizumab cohort) to the
earliest of the previously mentioned events.
§Cox proportional hazard model including adjustments for baseline age, sex, steroid
use, body mass index, smoking history, physician-assessed asthma severity (moderate
vs severe), and the presence or absence of the following comorbidities: chronic
obstructive pulmonary disease, congestive heart failure, depression,
hypercholesterolemia, hypertension, type 2 diabetes.
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of omalizumab was a possibility.19,20 While EXCELS was
reasonably well-balanced for malignancy risk factors and
showed similar rates of malignancy in the omalizumab and
non-omalizumab cohorts, CV risk was greater at baseline in the
omalizumab cohort,21 possibly the result of the indication for
omalizumab, such that the treated group included patients with
more severe asthma. Higher rates of CV/CBV SAEs in the oma-
lizumab cohort were noted when analyses were not adjusted for
potential confounders. The findings were similar in the subset
of CV/CBV SAEs meeting the definition of ATE. However, after
taking confounding imbalances between the cohorts into account,
using multivariate Cox regression analyses, stratification, and
propensity score analyses, the crude associations were
substantially reduced. We can expect that control of confounding
was imperfect, and that the adjusted differences that we reported
were affected by some further residual confounding, very likely in
the same direction as the confounding that was controlled for.
Research indicates that asthma itself and the use of asthma
medications may be independently associated with increased CV
risk.22-29 An analysis of data from 6792 patients in the
Multi-Ethnic Study of Atherosclerosis concluded that a subgroup
of patients with asthma requiring controller medications, such asICSs, had a higher rate of CV disease compared with the
subgroup without asthma.30 Additionally, as previously
published, greater asthma severity predicted a higher risk for
ATEs in the non-omalizumab cohort of EXCELS.28 Multiple
hypotheses exist for the observed association between asthma
and CV outcomes. Potential mechanisms include medications
used for treating asthma,31-33 most notably OCSs, which are
well known to increase the risk for CV risk factors such as
diabetes,34 and have been associated with an increased risk for
adverse CV/CBVoutcomes.35-37 In patients with severe asthma,
moderate to high exposure to chronic systemic corticosteroids
appears to increase the risk for complications (eg, infections,
CV events, metabolic events).38 Additionally, a more direct link
between asthma and CV disease has been suggested, by virtue
of systemic inflammation associated with asthma as well as
specific cytokine upregulation.39-41 For example, the subgroup
of patients with asthma requiring controller medications in the
Multi-Ethnic Study of Atherosclerosis30 had higher levels of the
inflammatory markers C-reactive protein and fibrinogen than
did the subgroups of patients without asthma and patients with
asthma not requiring controller medications. Clinically, studies
have confirmed that asthma severity measures, such as lung
function impairment, are an independent risk factor for CV
disease, and epidemiologic studies also have confirmed an
association between asthma and comorbid diseases that increase
CV risk, such as diabetes and chronic obstructive pulmonary
disease.34,42
Elevated serum IgE levels have been described in some CV
conditions and in patients with a positive history of CV
disease.43,44 Moreover, IgE has been shown to be positively
associated with CV risk.45 None of these studies provides strong
evidence that suggests that the anti-IgE properties of omalizumab
contribute to an increased risk for CV events. In summary, no
definitive biological relationship has been identified.
In our multivariate analysis, we were able to control for the
imbalance in prevalence of severe asthma (49.6% in the
omalizumab cohort vs 22.6% in the non-omalizumab cohort).
Nonetheless, the dichotomous severity scale is unlikely to have
captured all of the confounding by severity in data, leading to
residual confounding. Additionally, there are likely to be
unmeasured risk factors, including comorbid disease severity,
further confounding the estimates.
Our findings alsomust be interpreted in the context of these and
other limitations. For example, if the primary objective of
EXCELS had been to examine CV/CBV outcomes rather than
malignancies, more careful details about the CV risk factor
FIG 2. Kaplan-Meier plot of time to first adjudicated study-emergent ATE SAE.
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levels or glycosylated hemoglobin levels to measure diabetes
control, may have been collected. Second, ;90% of the patients
in the omalizumab cohort were being treated with omalizumab
before study enrollment. Consequently, only a minority of
patients in the omalizumab cohort were new users. The
experience of new users may well differ from that of prevalent
users, who constituted the majority of exposed patients in our
study. Additionally, 44.1% of study participants discontinued
before the full 5 years of follow-up was completed, although only
slightly more than one fourth of person-time was lost to
follow-up.12 Finally, the reported estimates are imprecise owing
to the relatively low numbers of CV/CBV events adjudicated to
the individual categories.
The results from EXCELS do not exclude a potential
increased risk for CV/CBV SAEs in patients treated
with omalizumab. After control for measured confounders,
however, the magnitude of the estimated increase in risk
was reduced considerably from the crude estimates. The
assessment of CV/CBV risk should take into account the
results from EXCELS and the pooled analysis of randomized
controlled trials.
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Clinical implications: Current asthma-management guidelines
should not be affected by the findings from this study of CV/
CBV SAEs in patients receiving omalizumab. However, health
care professionals should be aware of a possible association of
omalizumab with CV/CBV SAEs.REFERENCES
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FIG E1. Patient use of OCSs during EXCELS, by treatment cohort and asthma severity. BL, Baseline.
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TABLE E1. Cox proportional hazards model of time to first adjudicated study-emergent ATE SAEs (adjusted)
Main effect Estimate SE HR (95% CI)
Treatment (omalizumab* vs non-omalizumab) 0.278 0.188 1.321 (0.913-1.910)
Covariate
Age (>_65 vs <65 y) 1.003 0.187 2.725 (1.891-3.928)
Asthma severity (severe vs moderate) 0.088 0.176 1.091 (0.773-1.540)
Sex (female vs male) 20.326 0.178 0.722 (0.509-1.023)
Steroid use (periodic vs none) 20.014 0.216 0.986 (0.646-1.505)
Steroid use (chronic vs none) 0.480 0.250 1.616 (0.990-2.637)
BMI (30-<40 vs <30 kg/m2) 0.682 0.190 1.978 (1.364-2.869)
BMI (>_40 vs <30 kg/m2) 0.276 0.287 1.318 (0.751-2.313)
Smoking history (ever vs never) 0.441 0.174 1.555 (1.106-2.184)
History of type 2 diabetes (yes vs no) 0.623 0.204 1.864 (1.250-2.781)
History of chronic obstructive pulmonary disease (yes vs no) 0.450 0.217 1.568 (1.024-2.400)
History of coronary artery disease (yes vs no) 1.139 0.240 3.125 (1.954-4.997)
History of hypercholesterolemia (yes vs no) 0.310 0.201 1.363 (0.920-2.021)
History of congestive heart failure (yes vs no) 0.775 0.296 2.172 (1.215-3.880)
History of hypertension (yes vs no) 0.778 0.189 2.176 (1.502-3.153)
History of depression (yes vs no) 0.424 0.194 1.528 (1.044-2.235)
BMI, Body mass index; HR, hazard ratio.
*Patients, n 5 2818; events, n 5 46.
Patients, n 5 4980; events, n 5 101.
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TABLE E2. Daily use of asthma and allergy medications at baseline
Asthma medication
Non-omalizumab cohort Omalizumab cohort
Moderate asthma*
(n 5 2185)
Severe asthma*
(n 5 637)
Moderate asthma*
(n 5 2519)
Severe asthma*
(n 5 2482)
OCS use 533 (24.4) 191 (30.0) 695 (27.6) 712 (28.7)
Type of OCS
Chronic 100 (4.6) 56 (8.8) 133 (5.3) 240 (9.7)
Periodic 433 (19.8) 135 (21.2) 562 (22.3) 472 (19.0)
Asthma controller use 1524 (69.8) 542 (85.4) 1967 (78.1) 2205 (88.9)
Type of asthma controller§
ICS 1291 (59.1) 494/637 (77.8) 1673 (66.4) 1968 (79.4)
Long-acting b-agonist 1190 (54.5) 463 (72.9) 1602 (63.6) 1880 (75.8)
Leukotriene receptor antagonist 459 (21.0) 213 (33.5) 817 (32.4) 1073 (43.3)
Theophylline 44 (2.0) 47 (7.4) 96 (3.8) 237 (9.6)
Asthma quick-relief use 259 (11.9) 161 (25.4) 392 (15.6) 728 (29.4)
Type of quick-relief agent
Anticholinergic 59 (2.7) 57 (9.0) 126 (5.0) 263 (10.6)
Short-acting ß-agonist 247 (11.3) 161 (25.4) 386 (15.3) 711 (28.7)
Data are expressed as no. (%) of patients.
*Physician-assessed asthma severity at baseline.
Omalizumab, moderate asthma: n 5 2517; omalizumab, severe asthma: n 5 2480.
Non-omalizumab, moderate asthma: n 5 2183; non-omalizumab, severe asthma: n 5 635; omalizumab, severe asthma: n 5 2480.
§Non-omalizumab cohort (moderate asthma, n 5 2183, severe asthma, n 5 635); omalizumab cohort (moderate asthma, n 5 2519, severe asthma, n 5 2480).
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TABLE E3. Crude rates of adjudicated study-emergent ATE SAEs
Parameter
Non-omalizumab
cohort* (n 5 2,829)
Omalizumab
cohorty (n 5 5,007)
Crude rate difference
(95% CI)
Crude rate ratio
(95% CI)
No. of ATE SAEs 51 115 — —
PYs at risk for ATE SAEs 9,963 15,286 — —
Rate per 1000 PYs (95% CI) 5.12 (3.81-6.73) 7.52 (6.21-9.03) 2.40 (0.16-4.62) 1.47 (1.02-2.18)
No. of patients with ATE SAEs 46 101 — —
PYs at risk for ATE SAEs 9,904 15,160 — —
Rate per 1000 PYs (95% CI) 4.64 (3.40-6.19) 6.66 (5.43-8.10) 2.02 (0.15-3.89) 1.43 (1.00-2.08)
No. of ATE SAEs (excluding non-ATE deaths) 32 91 — —
Rate per 1000 PYs (95% CI) 3.21 (2.20-4.53) 5.95 (4.79-7.31) 2.74 (0.74-4.68) 1.85 (1.16-3.09)
*All non–omalizumab- or omalizumab-treated patients before any change in baseline treatment status.
After initiation of omalizumab treatment (non-omalizumab cohort) or >6 months after last omalizumab dose (omalizumab cohort).
Defined as the time from day 0 to the earliest of the following events: study completion, death, start of omalizumab treatment (non-omalizumab cohort), >6 months after
discontinuation of omalizumab (omalizumab cohort), or the last completed study visit date (discontinued patients). For patients who changed omalizumab treatment status, PYs at
risk were calculated from omalizumab start date (non-omalizumab cohort) or >6 months after the end date (omalizumab cohort) to the earliest of the previously mentioned events.
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TABLE E4. Rates of adjudicated study-emergent ATE SAEs, by propensity score stratum
Propensity score* stratum
Rate per 1000 PYsy (95% CI)
Rate difference
(95% CI)
Rate ratio
(95% CI)
Non-omalizumab
cohortz (n 5 2829)
Omalizumab
cohort (n 5 5007)
Unadjusted 4.64 (3.40 to 6.19) 6.66 (5.43 to 8.09) 2.02 (0.15 to 3.89) 1.43 (1.00 to 2.08)
Stratified
1 3.91 8.95 — —
2 2.58 8.37 — —
3 4.46 8.42 — —
4 6.34 6.81 — —
5 3.40 5.37 — —
6 3.58 5.22 — —
7 12.97 5.37 — —
8 2.22 7.76 — —
9 2.69 4.25 — —
10 4.58 6.32 — —
Adjusted 4.80 (2.76 to 6.84) 6.35 (5.04 to 7.65) 1.55 (–0.87 to 3.97) 1.32 (0.83 to 2.12)
*Predictive probability of a patient receiving omalizumab as a function of baseline characteristics; patients were stratified into deciles according to their propensity score (higher
scores/strata reflect a higher probability of receiving omalizumab).
Defined as the time from day 0 to the earliest of the following events: study completion, death, start of omalizumab treatment (non-omalizumab cohort), 6 months after
discontinuation of omalizumab (omalizumab cohort), first ATE SAE, or study visit date (discontinued patients).
All non–omalizumab- or omalizumab-treated patients before any change in baseline treatment status.
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